uniQure N.V.

NasdaqGS:QURE

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

Netherlands

Market Cap

USD 826.70 M

Share Price

USD 15.10

Avg Daily Volume

1,782,873

Change (1 day)

2.10%

Change (1 year)

230.42%

Change (YTD)

-14.50%

uniQure N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 20.20 M

uniQure N.V. Revenue is USD 20.20 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 6.30% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

uniQure N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 19.00 M, a -82.73% change year over year.
uniQure N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 110.02 M, a -79.06% change year over year.
uniQure N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 525.34 M, a 1,287.44% change year over year.
uniQure N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 37.86 M, a 505.92% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqGS: QURE

uniQure N.V.

CEO	Mr. Matthew Craig Kapusta CPA
IPO Date	Feb. 5, 2014
Location	Netherlands
Headquarters	Paasheuvelweg 25a
Employees	209
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.